Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Frovatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 3/20 | 1.00 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.86 |
| ▸ | DRD4 | P21917 | 1/20 | 0.86 |
| ▸ | HTR1E | P28566 | 1/20 | 0.86 |
| ▸ | HTR7 | P34969 | 1/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.86 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | HTR1F | P30939 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Frovatriptan SCHEMBL29360449 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL16365906 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL34410 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL3474278 | 0.99 | HTR1B (0.98) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL672784 | 0.94 | HTR1B (0.98) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL5489168 | 0.94 | HTR1B (0.98) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Frovatriptan SCHEMBL2321442 | 0.93 | HTR1B (1.00) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL7030069 | 0.89 | HTR1B (0.80) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL8018884 | 0.87 | HTR1A (0.78) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL8018888 | 0.87 | HTR1A (0.78) | HTR1BHTR1AHTR1DDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116211817-A | Fusartriptan succinate tablet and preparation process thereof | 正大制药（青岛）有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-2400986-B1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HELSINN HEALTHCARE SA (CH) | 2015-10-14 | — | — | EP | disclosed |
| EP-2816030-A1 | Process for the preparation of frovatriptan and its enantiomer | Duke Chem, S. A. (ES) | 2014-12-24 | — | — | EP | disclosed |
| WO-2014202717-A1 | PROCESS FOR THE PREPARATION OF FROVATRIPTAN AND ITS ENANTIOMER | DUKE CHEM, S.A. (ES) | 2014-12-24 | — | — | WO | disclosed |
| US-8673947-B2 | Enhanced migraine treatments based on ghrelin mimetics | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130289068-A1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-8486976-B2 | Enhanced migraine treatments based on ghrelin mimetics | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110257228-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING A TRIPTAN COMPOUND AND XYLITOL | ALMIRALL, S.A. (ES) | 2011-10-20 | — | — | US | disclosed |
| EP-2198889-A1 | Liquid pharmaceutical compositions comprising a triptan compound and Xylitol | Almirall, S.A. (ES) | 2010-06-23 | — | — | EP | disclosed |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080064725-A1 | INTRATHECAL ADMINISTRATION OF TRIPTAN COMPOSITIONS TO TREAT NON-MIGRAINE PAIN | BASBAUM, ALLAN | 2008-03-13 | — | — | US | disclosed |
| US-20080064725-A1 | INTRATHECAL ADMINISTRATION OF TRIPTAN COMPOSITIONS TO TREAT NON-MIGRAINE PAIN | BASBAUM, ALLAN | 2008-03-13 | — | — | US | disclosed |
| US-20070059254-A1 | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | TRANSORAL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070059254-A1 | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | TRANSORAL PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7049448-B2 | Process for the preparation of monoketals of 1,4-cyclohexanedione including 1, 4-cyclohexanedione mono-2,2-dimethyl trimethylene ketal | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-05-23 | — | — | US | disclosed |
| US-20040230063-A1 | Process for the preparation of monoketals of 1,4-cyclohexanedione including 1, 4-cyclohexanedione mono-2,2-dimethyl trimethylene ketal | DR. REDDY'S LABORATORIES LIMITED | 2004-11-18 | — | — | US | disclosed |
| US-20040023948-A1 | Fast-dispersing dosage form containing 5-HT1 agonists | CATALENT USA PAINTBALL, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289068-A1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HTR1E, HTR1B, HTR3B | HTR1B 2/4885HTR1D 6/4885HTR1A 4/4885 |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | IDO1, TPH1, IDO2 | HTR1B 21/4885HTR1D 71/4885HTR1A 18/4885 |
| US-20070059254-A1 | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | HTR5A, HTR1A, HTR3A | HTR1B 15/4885HTR1D 17/4885HTR1A 2/4885 |
| US-20080064725-A1 | INTRATHECAL ADMINISTRATION OF TRIPTAN COMPOSITIONS TO TREAT NON-MIGRAINE PAIN | OPRL1, OPRK1, TPSG1 | HTR1B 43/4885HTR1D 41/4885HTR1A 32/4885 |
| US-20040230063-A1 | Process for the preparation of monoketals of 1,4-cyclohexanedione including 1, 4-cyclohexanedione mono-2,2-dimethyl trimethylene ketal | KHK, KYAT1, KMO | HTR1B 396/4885HTR1D 214/4885HTR1A 432/4885 |
| US-20110257228-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING A TRIPTAN COMPOUND AND XYLITOL | SLC5A1, TREH, SLC5A2 | HTR1B 794/4885HTR1D 430/4885HTR1A 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.